Lamotrigine
Lamotrigine is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Lamotrigine; Generic name: LAMOTRIGINE; Drug class: Anti-epileptic Agent [EPC].
| Brand name | Lamotrigine |
|---|---|
| Generic name | LAMOTRIGINE |
| Drug class | Anti-epileptic Agent [EPC] |
| Manufacturer | Amneal Pharmaceuticals LLC |
| Used for | 1 INDICATIONS AND USAGE Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures (PGTC) and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. (1.1) conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). (1.2) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. (1.3) 1.1 Adjunctive Therapy Lamotrigine extended-release tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-o |
| Dosage | 2 DOSAGE AND ADMINISTRATION Lamotrigine extended-release tablets are taken once daily, with or without food. Tablets must be swallowed whole and must not be chewed, crushed, or divided. Do not exceed the recommended initial dosage and subsequent dose escalation. (2.1) Initiation of adjunctive therapy and conversion to monotherapy requires slow titration dependent on concomitant AEDs; the prescriber must refer to the appropriate algorithm in Dosage and Administration. (2.2, 2.3) Adjunctive therap |
| Warnings | WARNING: SERIOUS SKIN RASHES Lamotrigine extended-release can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric pat |
| Active ingredient(s) | LAMOTRIGINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0833d3df-2df1-4abd-abe0-7fb2c0253c80 |